tbuckley/cabot-search huggingface dataset:
Clinical Characteristics and Outcomes of Elderly Patients with Stage I Diffuse Large B-Cell Lymphoma: A Study By Jiangsu Cooperative Lymphoma Group (JCLG)
Authors: Wenyu Shi, Yi Xia, Yongle Li, Jiahao Zhou, Jing He, Weiying Gu, Bingzong Li, Tao Jia, Tingxun Lu, Ping Liu, Yue-Xin Cheng, Yuqing Miao, Xiaoyan Xie, Yunping Zhang, Xuzhang Lu, Chunling Wang, Min Xu, Jinning Shi, Weifeng Chen, Wanchuan Zhuang, Zhen Qian, Haiwen Ni, Yifei Chen, Jianyong Li
Journal: Blood (2023)
Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
Authors: Baptiste Le Calvez, Maxime Jullien, Jean-Hugues Dalle, Cécile Renard, Charlotte Jubert, Arthur Sterin, Catherine Paillard, Anne Huynh, Sarah Guenounou, Benedicte Bruno, Virginie Gandemer, Nimrod Buchbinder, Pauline Simon, Cecile Pochon, Anne Sirvent, Dominique Plantaz, Justyna Kanold, Fanny Rialland Battisti, Audrey Grain
Journal: Blood (2023)
Umbilical Cord Blood Stem Cells As Third-Party Adjuvant Infusion in Human Leukocyte Antigen Antibody-Positive Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Yujie Jiang, Yuying Wang, Dai Yuan, Xiaosheng Fang, Huiting Qu, Lingyan Zhang, Ying Li, Xin Wang
Journal: Blood (2023)
Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience
Authors: Ranjit Nair, Iyanuoluwa Ogundipe, Jillian Gunther, L. Jeffrey Medeiros, Preetesh Jain, Loretta J. Nastoupil, Chelsea Camille Pinnix, Luis Malpica, Sairah Ahmed, Roberto Miranda, Luis Fayad, Raphael E Steiner, Frederick Hagemeister, Hun Ju Lee, Maria Alma Rodriguez, Paolo Strati, Dai Chihara, Michael Wang, Yago Nieto, Jeremy Ramdial, Ajlan Al Zaki, Chijioke Nze, Michael R. Green, Bouthaina S. Dabaja, Jie Xu, Beenu Thakral, Sattva S. Neelapu, Francisco Vega, Christopher R. Flowers, Penny Fang, Jason Westin, Lei Feng, Swami P. Iyer
Journal: Blood (2023)
The Bone Marrow-Targeted Conditioning Stress Test Demonstrates Vertebrae Niche Being More Radio-Tolerant Than Femur, Indicating Skeleton Resilience and Global Heterogeneity
Authors: Srideshikan Sargur Madabushi, Ji Eun Lim, Hemendra Ghimire, Jeffrey Wong, Anthony Stein, Amandeep Salhotra, Monzr M. Al Malki, Susanta Hui
Journal: Blood (2023)
Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations
Authors: Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang
Journal: Blood (2023)
Spectrum of <i>ASXL1</i> Mutations Show Similar Impact on Outcomes in Patients with Myelofibrosis Undergoing Transplantation
Authors: Nico Gagelmann, Anita Badbaran, Christine Wolschke, Mathias Schäfersküpper, Dietlinde Janson, Francis A. Ayuk, Boris Fehse, Nicolaus Kroeger
Journal: Blood (2023)
Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema
Authors: Fabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi, Michele Clerico, Annalisa Chiappella, Domenico Russo, Riccardo Saccardi, Barbara Botto, Thomas Baldi, Francesca Tartaglia, Enrico Orciuolo, Massimiliano Gambella, Maria Chiara Tisi, Maurizio Martelli, Claudio Cartoni, Martina Di Palma, Massimo Martino, Paolo Corradini, Paola Fazi, Marco Vignetti, Alice Di Rocco
Journal: Blood (2023)
Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influence Efficacy Outcomes in the Phase-2 Study (IMAGINE)
Authors: Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Pankaj Malhotra, Alex Jose Pulikkottil, Jeetendra Kumar, Melina Soares, Sudeshna Dhar, Sandeepa Shetty, Mani Bharathi T.I., Gopinadh Jakka, Anne Roshan Joseph, Arun Kumar MG, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Giridhar K Chenji, Lakshmikanth Gandikota, Rahul Nahar, Anil Kamat
Journal: Blood (2023)
Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
Authors: Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood (2023)
Effect of a Crossover and Resistance Exercise Routine on IL-15 in Adults with Type B Acute Lymphoblastic Leukemia during the Induction Phase. Randomized Pilot Study
Authors: Adán Germán Gallardo-Rodríguez, Irma Olarte Carrillo, Adolfo Martínez Tovar, Rafael Cerón Maldonado, Humberto Baldemar Castellanos Sinco, Christian Omar Ramos Peñafiel
Journal: Blood (2023)
Pomalidomide, Dexamethasone, and Daratumumab Versus Other Triplet Regimens in Patients with Relapsed or Refractory Multiple Myeloma: A Population-Adjusted Indirect Treatment Comparison
Authors: Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang
Journal: Blood (2023)
Mutational Analysis of the Genome Stability Factor <i>BOD1L1</i> in Myeloproliferative Neoplasm
Authors: Martin R Higgs, Sofia Browne, Ryan Collinson, Kathy Fuller, Wendy N. Erber, Maria Kleppe, Ben Sirnosian, Georges Natsoulis, Belinda Guo, Hugh Young Rienhoff Jr.
Journal: Blood (2023)
Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Authors: Nina Caculitan, Josephine M. Cardarelli, Jack Khouri, Hyung C Suh, Muthalagu Ramanathan, Ann Woolfrey
Journal: Blood (2023)
Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients
Authors: Andrius Zucenka, Birutė Davainienė, Vilmantė Vaitekėnaitė, Rūta Čepulytė, Linas Davainis, Guoda Daukėlaitė, Lukas Kevličius, Regina Pileckytė, Igoris Trociukas, Laimonas Griškevičius
Journal: Blood (2023)
Research on Different Compound Combinations of Realgar-Indigo Naturalis Formula to Reverse APL Arsenic Resistance By Regulating Autophagy through mTOR Pathway
Authors: Ruibai Li, Yiming Pan, Chengyuan Xue, Guangda Li, Jieya Wu, Jingfang Zhang, Yayue Zhang, Jing Wang, Xinyi Chen, Ken H. Young, Li Hou
Journal: Blood (2023)
EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma
Authors: Junyuan Qi, Mingyuan Sun, Keshu Zhou, Chunyan Ji, Fei Lu, Chunkang Chang, Wenjun Zhang, Daniel Yang, Jiali Lu, Jisen Li, Ying Cheng, Yanfei Li
Journal: Blood (2023)
Correction
Journal: Journal of the American Academy of Dermatology (2023)

For the above article, Blauvelt et al, significant noncompliance at a study site was recently identified, and, as a result, 9 patients enrolled at that site should no longer be included in the analysis.After removing the 9 patients from the database, the data tables were regenerated and re-analyzed.The removal of these patients did not alter the findings or the overall conclusions; however, there are small numerical updates required for some data points.The article has been updated online.
Vernix caseosa reveals mechanistic clues linking maternal obesity to atopic dermatitis pathogenesis
Authors: Carolina Cabalín, Marisol Dibarrart, Juan José Núñez-Rosales, Miriam Faunes, Mónica Avaca, Patricia Ávalos, Jorge Fabres, María Javiera Álvarez-Figueroa, Cristian Vera-Kellet, Sergio Silva-Valenzuela, Claudia G. Sáez, Arturo Borzutzky
Journal: Journal of Allergy and Clinical Immunology (2023)
Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes
Authors: Federico Piramide, Filippo Turri, Daniele Amparore, Giuseppe Fallara, Ruben De Groote, Sophie Knipper, Christoph Wuernschimmel, Carlo Andrea Bravi, Edward Lambert, Fabrizio Di Maida, Nikolaos Liakos, Francesco Pellegrino, Iulia Andras, Alessandro Mastrorosa, Neeraja Tillu, Riccardo Mastroianni, Marco Paciotti, Mike Wenzel, Roberto Bianchi, Ettore di Trapani, Marcio Covas Moschovas, Giorgio Gandaglia, Marco Moschini, Frederiek D'Hondt, Bernando Rocco, Cristian Fiori, Antonio Galfano, Andrea Minervini, Giuseppe Simone, Alberto Briganti, Ottavio De Cobelli, Richard Gaston, Francesco Montorsi, Alberto Breda, Peter Wiklund, Francesco Porpiglia, Alexandre Mottrie, Alessandro Larcher, Paolo Dell'Oglio
Journal: European Urology (2023)
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
Authors: J.M. Piulats, C. Watkins, M. Costa-García, L. del Carpio, S. Piperno-Neumann, P. Rutkowski, J.C. Hassel, E. Espinosa, L. de la Cruz-Merino, S. Ochsenreither, A.N. Shoushtari, M. Orloff, A.K.S. Salama, H.M. Goodall, J.-F. Baurain, P. Nathan
Journal: Annals of Oncology (2023)

Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N = 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%. Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods.
Magnetic Chitosan Bionanocomposite Films as a Versatile Platform for Biomedical Hyperthermia
Authors: Ana Barra, Jacek K. Wychowaniec, Danielle Winning, Maria Margarida Cruz, Liliana P. Ferreira, Brian J. Rodriguez, Helena Oliveira, Eduardo Ruiz‐Hitzky, Cláudia Nunes, Dermot F. Brougham, Paula Ferreira
Journal: Advanced Healthcare Materials (2023)

Responsive magnetic nanomaterials offer significant advantages for innovative therapies, for instance, in cancer treatments that exploit on-demand delivery on alternating magnetic field (AMF) stimulus. In this work, biocompatible magnetic bionanocomposite films are fabricated from chitosan by film casting with incorporation of magnetite nanoparticles (MNPs) produced by facile one pot synthesis. The influence of synthesis conditions and MNP concentration on the films' heating efficiency and heat dissipation are evaluated through spatio-temporal mapping of the surface temperature changes by video-thermography. The cast films have a thickness below 100 µm, and upon exposure to AMF (663 kHz, 12.8 kA m
10-year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy
Authors: Guy Boeckxstaens, Stefanie Elsen, Ann Belmans, Vito Annese, Albert J Bredenoord, Olivier R Busch, Mario Costantini, Uberto Fumagalli, André J P M Smout, Jan Tack, Tim Vanuytsel, Giovanni Zaninotto, Renato Salvador
Journal: Gut (2023)

Objective As achalasia is a chronic disorder, long-term follow-up data comparing different treatments are essential to select optimal clinical management. Here, we report on the 10-year follow-up of the European Achalasia Trial comparing endoscopic pneumodilation (PD) with laparoscopic Heller myotomy (LHM). Design A total of 201 newly diagnosed patients with achalasia were randomised to either a series of PDs (n=96) or LHM (n=105). Patients completed symptom (Eckardt score) and quality-of-life questionnaires, underwent functional tests and upper endoscopy. Primary outcome was therapeutic success defined as Eckardt score &lt; 3 at yearly follow-up. Secondary outcomes were the need for retreatment, lower oesophageal sphincter pressure, oesophageal emptying, gastro-oesophageal reflux and the rate of complications. Results After 10 years of follow-up, LHM (n=40) and PD (n=36) were equally effective in both the full analysis set (74% vs 74%, p=0.84) and the per protocol set (74% vs 86%, respectively, p=0.07). Subgroup analysis revealed that PD was superior to LHM for type 2 achalasia (p=0.03) while there was a trend, although not significant (p=0.05), that LHM performed better for type 3 achalasia. Barium column height after 5 min at timed barium oesophagram was significantly higher for patients treated with PD compared with LHM, while other parameters, including gastro-oesophageal reflux, were not different. Conclusions PD and LHM are equally effective even after 10 years of follow-up with limited risk to develop gastro-oesophageal reflux. Based on these data, we conclude that PD and LHM can both be proposed as initial treatment of achalasia.
Decline in prevalence of tuberculosis following an intensive case finding campaign and the COVID-19 pandemic in an urban Ugandan community
Authors: Emily A Kendall, Peter J Kitonsa, Annet Nalutaaya, Katherine O Robsky, Kamoga Caleb Erisa, James Mukiibi, Adithya Cattamanchi, Midori Kato-Maeda, Achilles Katamba, David Dowdy
Journal: Thorax (2023)

Background Systematic screening is a potential tool for reducing the prevalence of tuberculosis (TB) and counteracting COVID-19-related disruptions in care. Repeated community-wide screening can also measure changes in the prevalence of TB over time. Methods We conducted serial, cross-sectional TB case finding campaigns in one community in Kampala, Uganda, in 2019 and 2021. Both campaigns sought sputum for TB testing (Xpert MTB/RIF Ultra) from all adolescents and adults. We estimated the prevalence of TB among screening participants in each campaign and compared characteristics of people with TB across campaigns. We simultaneously enrolled and characterised community residents who were diagnosed with TB through routine care and assessed trends in facility-based diagnosis. Results We successfully screened 12 033 community residents (35% of the estimated adult/adolescent population) in 2019 and 11 595 (33%) in 2021. In 2019, 0.94% (95% CI: 0.77% to 1.13%) of participants tested Xpert positive (including trace). This proportion fell to 0.52% (95% CI: 0.40% to 0.67%) in 2021; the prevalence ratio was 0.55 (95% CI: 0.40 to 0.75)). There was no change in the age (median 26 vs 26), sex (56% vs 59% female) or prevalence of chronic cough (49% vs 54%) among those testing positive. By contrast, the rate of routine facility-based diagnosis remained steady in the 8 months before each campaign (210 (95% CI: 155 to 279) vs 240 (95% CI: 181 to 312) per 100 000 per year). Conclusions Following an intensive initial case finding campaign in an urban Ugandan community in 2019, the burden of prevalent TB as measured by systematic screening had decreased by 45% in 2021, despite the intervening COVID-19 pandemic.
Neutrophil responses to RSV infection show differences between infant and adult neutrophils
Authors: Elisabeth Robinson, Shyam Sawhney, Mario Cortina-Borja, Anna L David, Claire M Smith, Rosalind L Smyth
Journal: Thorax (2023)

Introduction Respiratory syncytial virus (RSV) causes a severe respiratory condition, bronchiolitis, in infants but not in adults. Bronchiolitis is characterised by neutrophilic infiltration in the airways, but whether neutrophils enhance recovery from infection or contribute to its pathology remains unknown. Methods We used a novel in-vitro model to compare term umbilical cord blood (infant) (n=17 donors) and adult neutrophils (n=15 donors) during migration across RSV-infected differentiated human nasal airway epithelial cells (AECs) in a basolateral to apical direction. Results Greater numbers of infant neutrophils (mean (95% CI)) (336 684 (242 352 to 431 015)) migrated across RSV-infected AECs to the apical compartment (equivalent to the airway lumen) compared with adult neutrophils (56 586 (24 954 to 88 218)) (p&lt;0.0001). Having reached the apical compartment of infected AECs, much greater numbers of infant neutrophils (140 787 (103 117 to 178 456)) became apoptotic compared with adult (5853 (444 to 11 261)) (p=0.002). Infant neutrophils displayed much greater expression of CD11b, CD64, neutrophil elastase (NE) and myeloperoxidase (MPO) than adult neutrophils at baseline and at all points of migration. However, as adult neutrophils migrated, expression of CD11b, CD64, NE and MPO became greater than at baseline. Discussion The high proportion of infant neutrophils migrating across RSV-infected AECs correlates with the neutrophilic infiltrate seen in infants with severe RSV bronchiolitis, with large numbers undergoing apoptosis, which may represent a protective mechanism during infection. Compared with adult neutrophils, infant neutrophils already have high expression of surface markers before contact with AECs or migration, with less capacity to increase further in response to RSV infection or migration.
Endowing Polyetheretherketone with Anti‐Infection and Immunomodulatory Properties through Guanidination Carbon Dots Modification to Promote Osseointegration in Diabetes with MRSA Infection
Authors: Xinxin Bai, Xintian Zhang, Jiecheng Xiao, Xingyu Lin, Rongjie Lin, Rui Zhang, Xiaoqin Deng, Menghan Zhang, Wenqin Wei, Bin Lan, Shaohuang Weng, Min Chen
Journal: Advanced Healthcare Materials (2023)

Methicillin-resistant Staphylococcus aureus (MRSA) infection and compromised immunity are the severe complications associated with implantation surgery in diabetes mellitus. Enhancing the antibacterial and immunomodulatory properties of implants represents an effective approach to improve the osseointegration of implant in diabetes mellitus. Herein, guanidination carbon dots (GCDs) with antibacterial and immunoregulatory functions are synthesized. The GCDs demonstrate killing effect on MRSA without detectable induced resistance. Additionally, they promote the polarization of macrophages from the M1 to M2 subtype, with the inhibiting pro-inflammatory cytokines and promoting anti-inflammatory factors. Correspondingly, GCDs are immobilized onto sulfonated polyether ether ketone (SP@GCDs) using a polyvinyl butyraldehyde (PVB) coating layer through soaking-drying technique. SP@GCDs maintain stable antibacterial efficacy against MRSA for six consecutive days and retain the immunomodulatory function, while also possessing the long-term storage stability and biocompatibility of more than 6 months. Moreover, SP@GCDs significantly promote the proliferation and mineralization of osteoblasts. SP@GCDs facilitate osteogenesis through immunoregulatory. Additionally, SP@GCDs exert stable antibacterial and immune regulatory functions in implantation site of a diabetes rat, effectively promoting implant osseointegration regardless of the MRSA infection. These findings provide valuable insights into implant modification through designing nanomaterials with multifunction for enhancing osseointegration of diabetes mellitus, suggesting the promising clinical application prospects.
Telemedicine with special focus on allergic diseases and asthma—Status 2022: An <scp>EAACI</scp> position paper
Authors: Sylwia Smolinska, Florin‐Dan Popescu, Elena Izquierdo, Darío Antolín‐Amérigo, Oliver J. Price, Alberto Alvarez‐Perea, Ibon Eguíluz Gracia, Nikolaos G. Papadopoulos, Oliver Pfaar, Filippo Fassio, Karin Hoffmann‐Sommergruber, Stephanie Dramburg, Ioana Agache, Marek Jutel, Helen A. Brough, João A. Fonseca, Elizabeth Angier, Cristina Boccabella, Matteo Bonini, Audrey Dunn Galvin, Peter G. Gibson, Radoslaw Gawlik, Farah Hannachi, Ömer Kalayci, Ludger Klimek, Rebecca Knibb, Paolo Matricardi, Tomás Chivato
Journal: Allergy (2023)

Abstract Efficacious, effective and efficient communication between healthcare professionals (HCP) and patients is essential to achieve a successful therapeutic alliance. Telemedicine (TM) has been used for decades but during the COVID‐19 pandemic its use has become widespread. This position paper aims to describe the terminology and most important forms of TM among HCP and patients and review the existing studies on the uses of TM for asthma and allergy. Besides, the advantages and risks of TM are discussed, concluding that TM application reduces costs and time for both, HCP and patients, but cannot completely replace face‐to‐face visits for physical examinations and certain tests that are critical in asthma and allergy. From an ethical point of view, it is important to identify those involved in the TM process, ensure confidentiality and use communication channels that fully guarantee the security of the information. Unmet needs and directions for the future regarding implementation, data protection, privacy regulations, methodology and efficacy are described.
Underserved groups in dysphagia intervention trials in Parkinson’s disease: A scoping review
Authors: Julia Hirschwald, Lauren Finnegan, Jule Hofacker, Margaret Walshe
Journal: Ageing Research Reviews (2023)

Underserved groups in Parkinson's disease (PD) intervention studies are well recognised. However, it remains unclear whether these exclusions apply to oropharyngeal dysphagia (OD) intervention studies in PD. The aim of this scoping review was to identify characteristics of included participants and underserved groups in intervention studies in OD in PD.
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Authors: Xiangyu Wu, Tianhang Li, Rui Jiang, Xin Yang, Hongqian Guo, Rong Yang
Journal: Molecular Cancer (2023)

Abstract The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial immune-regulatory roles played by MHC-I molecules, the abnormal modulation of MHC-I expression and function could be hijacked by tumor cells to escape the immune surveillance and attack, thereby promoting tumoral progression and impairing the efficacy of cancer immunotherapy. Here we reviewed and discussed the recent studies and discoveries related to the MHC-I molecules and their multidirectional functions in the development of cancer, mainly focusing on the interactions between MHC-I and the multiple participators in the tumor microenvironment and highlighting the significance of targeting MHC-I for optimizing the efficacy of cancer immunotherapy and a deeper understanding of the dynamic nature and functioning mechanism of MHC-I in cancer.
The road to publication: Advice from journal editors
Authors: Cristian Navarrete-Dechent, Karalikkattil T. Ashique, John R. Ingram, Lidia Rudnicka, Yolanda Gilaberte, Johannes Ring, Dedee F. Murrell, Dirk Elston, Bruce H. Thiers
Journal: Journal of the American Academy of Dermatology (2023)